Jaguar Health (JAGX) Change in Receivables (2015 - 2026)
Jaguar Health (JAGX) posted quarterly Change in Receivables of -$1.5 million for Q1 2026, down 377.96% year-over-year from $522736.1 in Q1 2025, and down 1829.76% quarter-over-quarter from $84000.0 in Q4 2025.
Jaguar Health (JAGX) Change in Receivables (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Change in Receivables for 12 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 377.96% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$1.2 million (down 299.65% YoY), while the FY2025 annual figure was -$6000.0, up 98.64% from the prior year.
- Change in Receivables slipped to -$1.5 million in Q1 2026 per JAGX's latest filing, from $84000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $410000.0 in Q2 2023 and bottomed at -$1.5 million in Q1 2026.
- Historically, Change in Receivables has averaged -$96529.4 across 5 years, with a median of $54000.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Receivables sank 1137.21% — and 2025, when it surged 628.0%.
- Jaguar Health's Change in Receivables stood at $54000.0 in 2022, then jumped by 442.59% to $293000.0 in 2023, then dropped by 5.12% to $278000.0 in 2024, then sank by 69.78% to $84000.0 in 2025, then sank by 1829.76% to -$1.5 million in 2026.
- Business Quant data shows JAGX's Change in Receivables at -$1.5 million in Q1 2026, $84000.0 in Q4 2025, and $264000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | -1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.45 Mn |
| Mar 31, 2026 | -1.45 Mn |
| Dec 31, 2025 | 84,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Mar 31, 2025 | -304,000.00 |
| Mar 31, 2025 | -304,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Sep 30, 2024 | -50,000.00 |
| Sep 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -213,000.00 |
| Jun 30, 2024 | -213,000.00 |
| Mar 31, 2024 | -455,000.00 |
| Mar 31, 2024 | -455,000.00 |
| Dec 31, 2023 | 293,000.00 |
| Dec 31, 2023 | 293,000.00 |